Trial Profile

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary) ; Lenvatinib (Primary) ; MK-4830 (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Acronyms KEYMAKER-U06; Substudy 06B
Sponsors Merck Sharp & Dohme

08 Jan 2024 Planned End Date changed from 31 Dec 2026 to 20 Sep 2028.
08 Jan 2024 Planned primary completion date changed from 17 Feb 2025 to 7 Nov 2026.
17 Mar 2023 Planned End Date changed from 24 Mar 2027 to 31 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com